APA (7th ed.) Citation

Lin, J., Guo, Q., Guo, Z., Lu, T., Chen, G., Lin, S., . . . Pan, J. (2022). Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. Radiation Oncology, 17(1), 1. https://doi.org/10.1186/s13014-022-02073-8

Chicago Style (17th ed.) Citation

Lin, Jing, et al. "Stereotactic Body Radiotherapy Extends the Clinical Benefit of PD-1 Inhibitors in Refractory Recurrent/metastatic Nasopharyngeal Carcinoma." Radiation Oncology 17, no. 1 (2022): 1. https://doi.org/10.1186/s13014-022-02073-8.

MLA (9th ed.) Citation

Lin, Jing, et al. "Stereotactic Body Radiotherapy Extends the Clinical Benefit of PD-1 Inhibitors in Refractory Recurrent/metastatic Nasopharyngeal Carcinoma." Radiation Oncology, vol. 17, no. 1, 2022, p. 1, https://doi.org/10.1186/s13014-022-02073-8.